PXS Stock Overview
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Provexis plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0059 |
| 52 Week High | UK£0.009 |
| 52 Week Low | UK£0.0041 |
| Beta | 1.18 |
| 1 Month Change | -10.00% |
| 3 Month Change | -16.43% |
| 1 Year Change | -19.53% |
| 3 Year Change | -38.55% |
| 5 Year Change | 88.71% |
| Change since IPO | -90.75% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Provexis' (LON:PXS) Cash Burn Rate
Mar 05
We're Not Very Worried About Provexis' (LON:PXS) Cash Burn Rate
Jan 21We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
Jun 30We're Not Worried About Provexis' (LON:PXS) Cash Burn
Feb 15We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
Oct 28Shareholder Returns
| PXS | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | -10.0% | 1.5% | 2.3% |
| 1Y | -19.5% | -2.4% | 5.6% |
Return vs Industry: PXS underperformed the UK Personal Products industry which returned -2.4% over the past year.
Return vs Market: PXS underperformed the UK Market which returned 5.6% over the past year.
Price Volatility
| PXS volatility | |
|---|---|
| PXS Average Weekly Movement | 9.9% |
| Personal Products Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: PXS has not had significant price volatility in the past 3 months.
Volatility Over Time: PXS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2 | Ian Ford | www.provexis.com |
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company’s syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats.
Provexis plc Fundamentals Summary
| PXS fundamental statistics | |
|---|---|
| Market cap | UK£13.24m |
| Earnings (TTM) | -UK£496.59k |
| Revenue (TTM) | UK£598.08k |
22.1x
P/S Ratio-26.7x
P/E RatioIs PXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXS income statement (TTM) | |
|---|---|
| Revenue | UK£598.08k |
| Cost of Revenue | UK£318.64k |
| Gross Profit | UK£279.44k |
| Other Expenses | UK£776.03k |
| Earnings | -UK£496.59k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00022 |
| Gross Margin | 46.72% |
| Net Profit Margin | -83.03% |
| Debt/Equity Ratio | 0% |
How did PXS perform over the long term?
See historical performance and comparison